title: Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy.
authors.forename: Kenji
authors.initials: K
authors.lastname: Ishitsuka
authors.forename: Shiro
authors.initials: S
authors.lastname: Jimi
authors.forename: Victor S
authors.initials: VS
authors.lastname: Goldmacher
authors.forename: Olga
authors.initials: O
authors.lastname: Ab
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tamura
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019002:CD56 Antigen / Q000276:immunology*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000473:pathology*; D008453:Maytansine / Q000031:analogs & derivatives; D000068878:Trastuzumab; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D019002:CD56 Antigen; D008453:Maytansine; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine